8byp: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8byp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8byp OCA], [https://pdbe.org/8byp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8byp RCSB], [https://www.ebi.ac.uk/pdbsum/8byp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8byp ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8byp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8byp OCA], [https://pdbe.org/8byp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8byp RCSB], [https://www.ebi.ac.uk/pdbsum/8byp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8byp ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Botulinum neurotoxins (BoNTs) are the most potent toxins known and are used to treat an increasing number of medical disorders. All BoNTs are naturally co-expressed with a protective partner protein (NTNH) with which they form a 300 kDa complex, to resist acidic and proteolytic attack from the digestive tract. We have previously identified a new botulinum neurotoxin serotype, BoNT/X, that has unique and therapeutically attractive properties. We present the cryo-EM structure of the BoNT/X-NTNH/X complex at 3.1 A resolution. Unexpectedly, the BoNT/X complex is stable and protease resistant at both neutral and acidic pH and disassembles only in alkaline conditions. Using the stabilizing effect of NTNH, we isolated BoNT/X and showed that it has very low potency both in vitro and in vivo . Given the high catalytic activity and translocation efficacy of BoNT/X, low activity of the full toxin is likely due to the receptor-binding domain, which presents weak ganglioside binding and exposed hydrophobic surfaces. | Botulinum neurotoxins (BoNTs) are the most potent toxins known and are used to treat an increasing number of medical disorders. All BoNTs are naturally co-expressed with a protective partner protein (NTNH) with which they form a 300 kDa complex, to resist acidic and proteolytic attack from the digestive tract. We have previously identified a new botulinum neurotoxin serotype, BoNT/X, that has unique and therapeutically attractive properties. We present the cryo-EM structure of the BoNT/X-NTNH/X complex at 3.1 A resolution. Unexpectedly, the BoNT/X complex is stable and protease resistant at both neutral and acidic pH and disassembles only in alkaline conditions. Using the stabilizing effect of NTNH, we isolated BoNT/X and showed that it has very low potency both in vitro and in vivo . Given the high catalytic activity and translocation efficacy of BoNT/X, low activity of the full toxin is likely due to the receptor-binding domain, which presents weak ganglioside binding and exposed hydrophobic surfaces. | ||
Structure and activity of botulinum neurotoxin X.,Martinez-Carranza M, Skerlova J, Lee PG, Zhang J, Burgin D, Elliott M, Philippe J, Donald S, Hornby F, Henriksson L, Masuyer G, Beard M, Dong M, Stenmark P bioRxiv. 2023 Jan 11:2023.01.11.523524. doi: 10.1101/2023.01.11.523524 | Structure and activity of botulinum neurotoxin X.,Martinez-Carranza M, Skerlova J, Lee PG, Zhang J, Burgin D, Elliott M, Philippe J, Donald S, Hornby F, Henriksson L, Masuyer G, Beard M, Dong M, Stenmark P bioRxiv [Preprint]. 2023 Jan 11:2023.01.11.523524. doi: , 10.1101/2023.01.11.523524. PMID:36712025<ref>PMID:36712025</ref> | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
Latest revision as of 09:30, 17 October 2024
Botulinum neurotoxin serotype X in complex with NTNH/X
| ||||||||||||